506 related articles for article (PubMed ID: 25709099)
1. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
[TBL] [Abstract][Full Text] [Related]
2. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
[TBL] [Abstract][Full Text] [Related]
3. Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening.
Pulla VK; Sriram DS; Soni V; Viswanadha S; Sriram D; Yogeeswari P
Chem Biol Drug Des; 2015 Oct; 86(4):881-94. PubMed ID: 25850461
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
[TBL] [Abstract][Full Text] [Related]
5. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.
Watson M; Roulston A; Bélec L; Billot X; Marcellus R; Bédard D; Bernier C; Branchaud S; Chan H; Dairi K; Gilbert K; Goulet D; Gratton MO; Isakau H; Jang A; Khadir A; Koch E; Lavoie M; Lawless M; Nguyen M; Paquette D; Turcotte E; Berger A; Mitchell M; Shore GC; Beauparlant P
Mol Cell Biol; 2009 Nov; 29(21):5872-88. PubMed ID: 19703994
[TBL] [Abstract][Full Text] [Related]
6. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
[TBL] [Abstract][Full Text] [Related]
7. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Chen H; Wang S; Zhang H; Nice EC; Huang C
Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
[TBL] [Abstract][Full Text] [Related]
8. Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.
Tarrant JM; Dhawan P; Singh J; Zabka TS; Clarke E; DosSantos G; Dragovich PS; Sampath D; Lin T; McCray B; La N; Nguyen T; Kauss A; Dambach D; Misner DL; Diaz D; Uppal H
Toxicol Mech Methods; 2015 Mar; 25(3):201-11. PubMed ID: 25894564
[TBL] [Abstract][Full Text] [Related]
9. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase.
Zhang RY; Qin Y; Lv XQ; Wang P; Xu TY; Zhang L; Miao CY
Anal Biochem; 2011 May; 412(1):18-25. PubMed ID: 21211508
[TBL] [Abstract][Full Text] [Related]
10. Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Dragovich PS; Bair KW; Baumeister T; Ho YC; Liederer BM; Liu X; Liu Y; O'Brien T; Oeh J; Sampath D; Skelton N; Wang L; Wang W; Wu H; Xiao Y; Yuen PW; Zak M; Zhang L; Zheng X
Bioorg Med Chem Lett; 2013 Sep; 23(17):4875-85. PubMed ID: 23899614
[TBL] [Abstract][Full Text] [Related]
11. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.
Shames DS; Elkins K; Walter K; Holcomb T; Du P; Mohl D; Xiao Y; Pham T; Haverty PM; Liederer B; Liang X; Yauch RL; O'Brien T; Bourgon R; Koeppen H; Belmont LD
Clin Cancer Res; 2013 Dec; 19(24):6912-23. PubMed ID: 24097869
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents.
Lucas S; Soave C; Nabil G; Ahmed ZSO; Chen G; El-Banna HA; Dou QP; Wang J
Recent Pat Anticancer Drug Discov; 2017; 12(3):190-207. PubMed ID: 28637419
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
Sharma P; Xu J; Williams K; Easley M; Elder JB; Lonser R; Lang FF; Lapalombella R; Sampath D; Puduvalli VK
Neuro Oncol; 2022 Feb; 24(2):229-244. PubMed ID: 34260721
[TBL] [Abstract][Full Text] [Related]
14. Advances in NAD-Lowering Agents for Cancer Treatment.
Ghanem MS; Monacelli F; Nencioni A
Nutrients; 2021 May; 13(5):. PubMed ID: 34068917
[TBL] [Abstract][Full Text] [Related]
15. Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death.
Velma GR; Krider IS; Alves ETM; Courey JM; Laham MS; Thatcher GRJ
J Med Chem; 2024 Apr; 67(8):5999-6026. PubMed ID: 38580317
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis induced by NAD depletion is inhibited by KN-93 in a CaMKII-independent manner.
Takeuchi M; Yamamoto T
Exp Cell Res; 2015 Jul; 335(1):62-7. PubMed ID: 26024774
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G
J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881
[TBL] [Abstract][Full Text] [Related]
18. NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism.
Burgos ES
Curr Med Chem; 2011; 18(13):1947-61. PubMed ID: 21517777
[TBL] [Abstract][Full Text] [Related]
19. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
Chini CC; Guerrico AM; Nin V; Camacho-Pereira J; Escande C; Barbosa MT; Chini EN
Clin Cancer Res; 2014 Jan; 20(1):120-30. PubMed ID: 24025713
[TBL] [Abstract][Full Text] [Related]
20. Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.
Ozgencil F; Eren G; Ozkan Y; Guntekin-Ergun S; Cetin-Atalay R
Bioorg Med Chem; 2020 Jan; 28(1):115217. PubMed ID: 31818629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]